Tipped to hit $1bn, GSK’s Shingrix gains committee approval

06:26 EDT 14 Sep 2017 | pharmaphorum

GlaxoSmithKline’s shingles vaccine Shingrix has gained the unanimous backing of an FDA advisory committee. The Vaccines and Related Biological Products Advisory Committee vote sets the product up for an FDA approval, which is expected on 24 Octo...

Original Article: Tipped to hit $1bn, GSK’s Shingrix gains committee approval


More From BioPortfolio on "Tipped to hit $1bn, GSK’s Shingrix gains committee approval"

Quick Search

Relevant Topics

GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...